ArticleCurrent oncology (Toronto, Ont.)2026
Clinical Outcomes and Immune-Related Adverse Events in Metastatic Non-Squamous NSCLC Treated with First-Line Pembrolizumab-Chemotherapy: A Real-World Study from Serbia.
Zlatan Bojić et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.